ProQR Therapeutics today announced positive results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations.
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … on ARVOLearn , ARVO’s online learning platform. Details of ProQR’s presentation are as follows: Presenter: Stephen R. …
… ProQR Announces Closing of Underwritten Public Offering of … share. All of the shares are being offered by ProQR. The closing included the full exercise of the … securities laws of any such state or jurisdiction. About ProQRProQR Therapeutics is dedicated to changing lives …